Evoke Pharma Statistics
Share Statistics
Evoke Pharma has 1.49M
shares outstanding. The number of shares has increased by -82.64%
in one year.
| Shares Outstanding | 1.49M |
| Shares Change (YoY) | -82.64% |
| Shares Change (QoQ) | 0.46% |
| Owned by Institutions (%) | 6.09% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 802 |
| FTD / Avg. Volume | 4.14% |
Short Selling Information
The latest short interest is 25.89K, so 1.73% of the outstanding
shares have been sold short.
| Short Interest | 25.89K |
| Short % of Shares Out | 1.73% |
| Short % of Float | 1.74% |
| Short Ratio (days to cover) | 1.15 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | 4.48 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | -1.13 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Evoke Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.66,
with a Debt / Equity ratio of 0.
| Current Ratio | 1.66 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.95 |
| Interest Coverage | 10.38 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $3,416,471,666,666.67 |
| Profits Per Employee | $-1,784,064,666,666.67 |
| Employee Count | 3 |
| Asset Turnover | 585045.43 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -42.2% in the
last 52 weeks. The beta is 0.15, so Evoke Pharma's
price volatility has been higher than the market average.
| Beta | 0.15 |
| 52-Week Price Change | -42.2% |
| 50-Day Moving Average | 3.01 |
| 200-Day Moving Average | 4.42 |
| Relative Strength Index (RSI) | 60.39 |
| Average Volume (20 Days) | 19,370 |
Income Statement
In the last 12 months, Evoke Pharma had revenue of 10,249.4B
and earned -5,352.2B
in profits. Earnings per share was -3823317.97.
| Revenue | 10,249.4B |
| Gross Profit | 10,249.4B |
| Operating Income | -5,204.1B |
| Net Income | -5,352.2B |
| EBITDA | -5,204.1B |
| EBIT | -5,853.6B |
| Earnings Per Share (EPS) | -3823317.97 |
Full Income StatementBalance Sheet
The company has 13.6M in cash and 5.16M in
debt, giving a net cash position of 8.44M.
| Cash & Cash Equivalents | 13.6M |
| Total Debt | 5.16M |
| Net Cash | 8.44M |
| Retained Earnings | -128,791.6B |
| Total Assets | 17.52M |
| Working Capital | 6.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -5.46M
and capital expenditures 0, giving a free cash flow of -5.46M.
| Operating Cash Flow | -5.46M |
| Capital Expenditures | n/a |
| Free Cash Flow | -5.46M |
| FCF Per Share | -3.9 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -50.77% and -52.22%.
| Gross Margin | 100% |
| Operating Margin | -50.77% |
| Pretax Margin | -52.22% |
| Profit Margin | -52.22% |
| EBITDA Margin | -50.77% |
| EBIT Margin | -50.77% |
| FCF Margin | n/a |
